Dr. Hayes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1211 Union Ave
Ste 300
Memphis, TN 38104Phone+1 901-516-0792Fax+1 901-266-6415- Is this information wrong?
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
- Boston University Medical CenterResidency, Internal Medicine, 1997 - 2000
- University of North Carolina at Chapel Hill School of MedicineClass of 1996
Certifications & Licensure
- TN State Medical License 2017 - 2025
- MS State Medical License 2017 - 2024
- NC State Medical License 2004 - 2024
- MA State Medical License 1999 - 2006
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
- Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN Start of enrollment: 2011 Jan 01
- Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Publications & Presentations
PubMed
- Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer: The Piedmont Study.Joel R Eisner, Gregory M Mayhew, James M Davison, Kirk D Beebe, Yoichiro Shibata, Yuelong Guo, Carol Farhangfar, Farhang Farhangfar, Joshua M Uronis, Jeffrey M Conroy,...> ;Clinical Cancer Research. 2023 Aug 15
- 1 citationsSequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients.Nancy Gillis, Amy S Etheridge, Sushant A Patil, D Neil Hayes, Michele C Hayward, J Todd Auman, Joel S Parker, Federico Innocenti> ;The Pharmacogenomics Journal. 2023 Jul 1
- 10 citationsNFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells.Li Guan, Dhanya K Nambiar, Hongbin Cao, Vignesh Viswanathan, Shirley Kwok, Angela B Hui, Yuan Hou, Rachel Hildebrand, Rie von Eyben, Brittany J Holmes, Junfei Zhao, Ch...> ;Cancer Research. 2023 Mar 15
- Join now to see all
Journal Articles
- Identification and Validation of Novel Microenvironment-Based Immune Molecular Subgroups of Head and Neck Squamous Cell Carcinoma: Implications for ImmunotherapyJ Ma, D N Hayes, A Dimitrios Colevas, N Lee, Annals of Oncology
Press Mentions
- Next-Generation Sequencing Assay Validated Across Labs, Tumor TypesMay 12th, 2017
Professional Memberships
- Member
Hospital Affiliations
- Methodist Healthcare Memphis HospitalsMemphis, Tennessee
- Regional One HealthMemphis, Tennessee
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: